
Eric Singhi/X
Jun 12, 2025, 19:16
Eric K. Singhi: U.S. FDA Approved Taletrectinib for ROS1+ mNSCLC
Eric K. Singhi, Thoracic Medical Oncologist at MD Anderson Cancer Center, shared a post on X:
“U.S. FDA approves taletrectinib for ROS1+ mNSCLC.
Treatment-naïve:
– ORR: 90% (TRUST-I), 85% (TRUST-II)
– DOR ≥12 mo: 72%, 63%TKI-pretreated:
– ORR: 52% (TRUST-I), 62% (TRUST-II)
– DOR ≥6 mo: 74%, 83%Liver tox, ILD/pneumonitis, QTc, hyperuricemia, myalgia, fractures.”
More posts featuring Eric Singhi on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 3, 2025, 17:51
Jul 3, 2025, 17:10
Jul 3, 2025, 16:01